The North America Thyroid Ablation Devices Market should witness market growth of 12.5% CAGR during the forecast period (2022-2028).
Certain factors aid in the higher prevalence of thyroid cancer. When an individual isexposed to radiationor receivesradiation to the neck and head as a baby or young child, the chances of getting thyroid cancer increase. Moreover, if a person has thyroid cancer or thyroid illness in theirfamily, hasa goiter history, or possessesa genetic disorder like the RET gene-related multiple endocrine neoplasia type 2 syndrome (MEN2), their chances of acquiring thyroid cancer increase.
Due to the rising incidence of thyroid nodulesand thyroid cancer, there is a rising demand for both thyroid ablation treatments and devices. Additionally, the introduction of technologically advanced ablation methods and the growing inclination for less invasive surgeries are anticipated to fuel market expansion. Presently,the most popular and effective methods for treating thyroid cancer and nodules are ablation methods.
The CDC claims that the leading cause of death and disability/impairment in the US is a chronic disease. Therefore, RFA technology operations will probably be needed as a result of the rise in chronic diseases in the US. In the United States, there were reportedly 915,664 thyroid cancer patients in 2019. In this nation, thyroid cancer affects about 33,000 women and 12,000 men annually, killing about 950 men and 1,100 women. Thyroid cancer was previously increasing more quickly than any other malignancy in the US. Increased detection through imaging tests like MRI orCT scans performed for other medical issues was mostly responsible for this. The strict diagnostic criteria have helped in decreasing the incidence of thyroid cancerby roughly 2% per year since 2014.This has helped in more people adopting for thyroid cancer and nodules ablation treatment.
The US market dominated the North America Thyroid Ablation Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $78,493.1 Thousands by 2028. The Canada market is poised to grow at a CAGR of 15% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 14% during (2022-2028).
Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Specialty Centers and Others. Based on Type, the market is segmented into Radiofrequency Ablation, Microwave Ablation and Others. Based on Application, the market is segmented into Thyroid Cancer and Thyroid Nodules. Based on Product, the market is segmented into Thermal-based Devices and Non-thermal-based Devices. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Boston Scientific Corporation, Integra LifeSciences Holdings Corporation, Johnson & Johnson, Theraclion SA, Olympus Corporation, Terumo Corporation, BVM Medical Limited, MedWaves, Inc., and STARmed Co. Ltd.
Certain factors aid in the higher prevalence of thyroid cancer. When an individual isexposed to radiationor receivesradiation to the neck and head as a baby or young child, the chances of getting thyroid cancer increase. Moreover, if a person has thyroid cancer or thyroid illness in theirfamily, hasa goiter history, or possessesa genetic disorder like the RET gene-related multiple endocrine neoplasia type 2 syndrome (MEN2), their chances of acquiring thyroid cancer increase.
Due to the rising incidence of thyroid nodulesand thyroid cancer, there is a rising demand for both thyroid ablation treatments and devices. Additionally, the introduction of technologically advanced ablation methods and the growing inclination for less invasive surgeries are anticipated to fuel market expansion. Presently,the most popular and effective methods for treating thyroid cancer and nodules are ablation methods.
The CDC claims that the leading cause of death and disability/impairment in the US is a chronic disease. Therefore, RFA technology operations will probably be needed as a result of the rise in chronic diseases in the US. In the United States, there were reportedly 915,664 thyroid cancer patients in 2019. In this nation, thyroid cancer affects about 33,000 women and 12,000 men annually, killing about 950 men and 1,100 women. Thyroid cancer was previously increasing more quickly than any other malignancy in the US. Increased detection through imaging tests like MRI orCT scans performed for other medical issues was mostly responsible for this. The strict diagnostic criteria have helped in decreasing the incidence of thyroid cancerby roughly 2% per year since 2014.This has helped in more people adopting for thyroid cancer and nodules ablation treatment.
The US market dominated the North America Thyroid Ablation Devices Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $78,493.1 Thousands by 2028. The Canada market is poised to grow at a CAGR of 15% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 14% during (2022-2028).
Based on End-use, the market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Specialty Centers and Others. Based on Type, the market is segmented into Radiofrequency Ablation, Microwave Ablation and Others. Based on Application, the market is segmented into Thyroid Cancer and Thyroid Nodules. Based on Product, the market is segmented into Thermal-based Devices and Non-thermal-based Devices. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Boston Scientific Corporation, Integra LifeSciences Holdings Corporation, Johnson & Johnson, Theraclion SA, Olympus Corporation, Terumo Corporation, BVM Medical Limited, MedWaves, Inc., and STARmed Co. Ltd.
Scope of the Study
By End-use
- Hospitals
- Ambulatory Surgical Centers (ASCs)
- Cancer Specialty Centers
- Others
By Type
- Radiofrequency Ablation
- Microwave Ablation
- Others
By Application
- Thyroid Cancer
- Thyroid Nodules
By Product
- Thermal-based Devices
- Non-thermal-based Devices
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Boston Scientific Corporation
- Integra LifeSciences Holdings Corporation
- Johnson & Johnson
- Theraclion SA
- Olympus Corporation
- Terumo Corporation
- BVM Medical Limited
- MedWaves, Inc.
- STARmed Co. Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America Thyroid Ablation Devices Market by End-use
Chapter 4. North America Thyroid Ablation Devices Market by Type
Chapter 5. North America Thyroid Ablation Devices Market by Application
Chapter 6. North America Thyroid Ablation Devices Market by Product
Chapter 7. North America Thyroid Ablation Devices Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Medtronic PLC
- Boston Scientific Corporation
- Integra LifeSciences Holdings Corporation
- Johnson & Johnson
- Theraclion SA
- Olympus Corporation
- Terumo Corporation
- BVM Medical Limited
- MedWaves, Inc.
- STARmed Co. Ltd.
Methodology
LOADING...
Related Reports
From
From
From
Global Ablation Devices Market Report by Device Technology, Application, End User, and Region 2023-2028
- Report
- 141 Pages
- Global
From
Global Ablation Technology Market Report and Forecast 2024-2032
- Report
- 160 Pages
- Global
From
About the Thyroid Ablation Devices Market
The Thyroid Ablation Devices market is a subset of the larger Surgical Devices market. It includes devices used to ablate, or destroy, the thyroid gland. These devices are used to treat thyroid cancer, hyperthyroidism, and other thyroid-related conditions. The devices typically use either radiofrequency ablation or cryoablation to destroy the thyroid tissue. The market is driven by the increasing prevalence of thyroid-related conditions, as well as technological advancements in ablation Read more
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
